Overview

This trial is active, not recruiting.

Condition epilepsies, partial
Treatments figure-of-eight active rtms coil, round active rtms coil, sham rtms coil (figure-of-eight)
Sponsor Universitaire Ziekenhuizen Leuven
Start date November 2012
End date May 2015
Trial size 20 participants
Trial identifier NCT01745952, s52486

Summary

The investigators will treat patients with fully characterized refractory unifocal neocortical epilepsy with a technique that delivers magnetic waves (transcranial magnetic stimulation, TMS) to the region that causes the epilepsy. Active rTMS applied over the epileptogenic focus will reduce seizure frequency compared with sham rTMS.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model crossover assignment
Masking double blind (subject, caregiver, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
figure-of-eight active rtms coil
navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
(Experimental)
rTMS is administered using the round active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
round active rtms coil
navigated rTMS over epileptogenic focus using round active rTMS coil
(Sham Comparator)
rTMS is administered using the figure-of-eight sham coil, over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
sham rtms coil (figure-of-eight)
Magstim placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue

Primary Outcomes

Measure
50% responder rate after active rTMS treatment compared with placebo treatment
time frame: week 12 after each intervention

Secondary Outcomes

Measure
Percentage of seizure reduction after active rTMS treatment compared with placebo treatment
time frame: week 12 after each treatment

Eligibility Criteria

Male or female participants from 16 years up to 75 years old.

Inclusion Criteria: - fully characterized refractory unifocal neocortical epilepsy (i.e. the epileptogenic zone is well defined) - on a stable drug regimen for at least one month, - able to complete a seizure dairy either by the patient or by a significant other Exclusion Criteria: - Metal in the head including deep brain stimulators, aneurysmal clips, ventricular shunts, cochlear implants, ossicular reconstruction of the middle ear… - pacemaker, implantable cardioverter-defibrillator (ICD) - psychogenic non-epileptic seizures and other non-epileptic spells

Additional Information

Official title Multimodal Image-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Refractory Partial Epilepsy.
Principal investigator Van Paesschen Wim, MD, PhD
Description 1. Background and study aims Epilepsy is a disease that causes repetitive seizures. In 60% of people with epilepsy, these seizures start in a small zone of the brain (focal or partial epilepsy). This zone can be in the depth of the temporal lobe (mesial temporal lobe epilepsy) or in another brain region (neocortical epilepsy). Even with optimal medical care, up to 30% of people with epilepsy continue to have seizures. The investigators will treat people with neocortical partial epilepsy with a technique that delivers magnetic waves (transcranial magnetic stimulation, TMS) to the region that causes the epilepsy. The investigators have good reasons to believe that there will be fewer seizures during several weeks after treatment. 2. Who can participate? You have neocortical focal epilepsy. A doctor who specializes in epilepsy made this diagnosis. You had at least one seizure recorded while in an epilepsy monitoring unit. You had an MRI scan of the brain. You can deliver us all the results of the tests you had. You continue to have more than 4 seizures a month. You tried a least two different schemes of anti-epileptic drugs as prescribed by your doctor and those schemes were well tolerated. Nevertheless this never cured the seizures. You are older than 16 years. You don't plan to become pregnant during the study. You need to faithfully continue your treatment as prescribed by your doctor and don't change the drugs you take from at least 4 weeks before the study until 8 weeks after the last TMS session. You need to be able to keep a diary of your seizures. 3. What does the study involve? You will need to come to the hospital every weekday during two consecutive weeks, every three months during nine months for the TMS-treatment. So you will have three treatment sessions. You will have a brain scan (FDG-PET) before the first treatment and after each session. The magnetic pulses will be delivered differently during each of the three treatment sessions: once on a rather small area of the brain, once on a larger brain area and once using a dummy coil, i.e. you will have two active treatment sessions and one dummy or placebo session. The investigators will not tell in which order they deliver the treatments. 4. What are the possible benefits and risks of participating? The investigators have good reasons to believe you will have fewer seizures in the weeks following the active treatment.
Trial information was received from ClinicalTrials.gov and was last updated in May 2015.
Information provided to ClinicalTrials.gov by Universitaire Ziekenhuizen Leuven.